What specifically changed in the AMGN analyst rating on February 04, 2026?

Bank of America Securities maintained an Underperform rating on Amgen Inc. on February 04, 2026, citing a shift of pelacarsen readthrough to mid-2026. The note did not provide a new price target.

How should investors interpret an Underperform from BofA for AMGN?

An Underperform suggests BofA expects Amgen to lag the market or peers in the near term. Investors should weigh the note against other analysts and the company’s fundamentals before changing a long-term position.

Did the BofA note include an AMGN price target?

No. The February 04, 2026 Bank of America note maintained Underperform but did not publish a fresh price target, so market moves reflected catalyst timing and sentiment.

How does Meyka AI rate AMGN and what does that grade mean?

Meyka AI rates AMGN with a grade of B+. The grade factors S&P 500 comparison, sector performance, growth, key metrics, and analyst consensus. Grades are informational and not financial advice.

Analyst Ratings

Bank of America Maintains Underperform on Amgen Inc (AMGN) Feb 2026

ByDanny Kontos February 5, 2026

Bank of America Securities maintained an Underperform rating on Amgen Inc. (AMGN) on February 04, 2026. The AMGN analyst rating highlights BofA’s view that near-term catalysts have shifted, citing a pelacarsen readthrough move to mid-2026. That view sits against a recent -7.64% decline in Amgen’s share price, equal to $-27.99 since the note. Investors should read the rating as a firm-specific take from a major house, not a consensus downgrade or a new price target. For live context, see BofA’s note on StreetInsider source.